What is the physiological function of Yes-associated protein-1 (Yap1), a susceptibility gene for polycystic ovary syndrome (PCOS), in ovarian granulosa cells (GCs)?
Introduction
Polycystic ovary syndrome (PCOS) is a common gynecologic and endocrine disease with multiple short and long-term consequences (Caldwell et al., 2014) . It is associated with hyperandrogenism and is one of the most common causes for anovulation in women. It increases the risk for metabolic syndrome, type 2 diabetes and cardiovascular disease. However, its etiology remains unclear. PCOS is thought to be the result of the interaction between predisposing genetic variants with environmental factors and strongly depends on ethnicity.
There is substantial evidence to support a role for androgens in the development of PCOS. A variety of animal models for PCOS have been established by increasing androgen exposure, supporting a role for androgens in the pathogenesis of PCOS (Manneras et al., 2009; Motta, 2010) . However, some androgens can be aromatized into estrogens leading to confusion on which PCOS traits are primary mediated via androgenic or estrogenic mechanisms (Walters, 2016; Zhang et al., 2016) . Indeed, genetic studies in mouse models indicated that both intraovarian androgen and estrogen signals are essential for normal follicle development and ovulation (Emmen et al., 2005; Sen and Hammes, 2010; Sen et al., 2014) . Consistently, many PCOS patients suffer from both hyperandrogenism and hyperestrogenism, followed by anovulation or oligo-ovulation (Fanta, 2013) . However, the mechanism(s) by which androgen or estrogen excess blocks ovulation is unclear.
The characteristic of familial aggregation makes PCOS worthy of genetic investigation. In order to identify susceptibility genes, Chen and colleagues conducted a genome-wide association study (GWAS) in a Chinese Han population, and reported multiple susceptibility loci associated with PCOS (Chen et al., 2011; Cui et al., 2013) . Several interesting SNPs aggregated in the gene Yap1 (Yes-associated Protein) on chromosome 11q13 . Therefore, Yap1 appears to be a new susceptibility gene for PCOS in women. Our recent investigations revealed that maternal YAP1 accumulated during oogenesis and is essential for zygotic genome activation (Yu et al., 2016) . We also reported that high YAP1 expression is a prognostic marker for ovarian cancer progression and a potential target for ovarian cancer treatment (Xia et al., 2014a (Xia et al., , 2014b . However, the role of YAP1 in ovarian follicle growth and ovulation has never been investigated previously.
YAP1 is a pivotal transcriptional co-activator of the Hippo signaling pathway, which governs organ volume and plays an important role in tumorigenesis such as breast, lung and ovarian cancers Pan, 2007; Shen et al., 2015) . Combining the GWAS data and previous information on YAP1, we speculate that YAP1 may play an important role in maintaining normal ovarian functions, and its deregulation contributes to the formation of PCOS.
In this study, we provide novel evidence in a mouse model that YAP1 is required for proliferation of ovarian granulosa cells (GCs), but is down-regulated by LH through the extracellular-regulated kinase-1/ 2 (ERK1/2) cascade. Acute hyperandrogenism blocks LH actions and causes oligo-ovulation by activating YAP1. These findings not only reveal the role of YAP1 in maintaining normal ovarian functions, but also link YAP1 deregulation to the pathogenesis of PCOS.
Materials and Methods

Mice
Wild-type C57/BL6 mice were obtained from the Center of Experimental Animals, Zhejiang University. Mice with GC-specific knockout of Erk1/2 driven by Cyp19-Cre (Erk1 −/− ;Erk2 fl/fl ;Cyp19-Cre, Erk1/2 gc−/− ) were previously reported (Fan et al., 2009) . Animals were housed under a 14:10 h, light: dark schedule, provided food and water ad libitum. All mice used were handled with care and according to the Animal Research Committee guidelines of Zhejiang University.
To study ovarian responses to exogenous gonadotropins, female mice at postnatal day (PD)-21~23 were analyzed to avoid the complexity of ovarian functions associated with estrous cycles and endogenous surges of gonadotropins. Immature mice were injected intraperitoneally with five IU pregnant mare serum gonadotrophin (PMSG) (Ningbo Sansheng Pharmaceutical Co., Ltd, PR China) to stimulate preovulatory follicle development followed 44 h later with five IU hCG (Ningbo Sansheng Pharmaceutical Co., Ltd, PR China) to stimulate ovulation. For dihydrotestosterone (DHT) treatments, female mice at PD23 were injected intraperitoneally with five IU PMSG followed 44 h later with five IU hCG alone (as control) or five IU hCG plus 100 μg DHT, which was dissolved in 0.1 ml DMSO. The dosage used was based on our experiment results in cultured GCs. Mice were sacrificed at indicated time points post-hCG (n = 6 for each time point), and ovaries were isolated for histological analyses.
Ovulated oocytes were collected from oviducts, and were digested with hyaluronidase (Sigma) to remove cumulus cells in M2 medium (M7167; SigmaAldrich). Numbers of ovulated oocytes were counted under a stereoscope.
GC culture
GCs were harvested from PMSG-primed (24 h), 23 days old mice as described previously . Briefly, undifferentiated GCs were released from antral follicles by puncturing with a 26.5 gauge needle. Cells were cultured at a density of 1 × 10 6 cells in in 24-well culture dishes.
Each well contained 500 μl DMEM (Invitrogen) supplemented with 5% (v/ v) fetal bovine serum (Invitrogen), 100 U/mL penicillin and 100 μg/mL streptomycin. To induce the expression of LH target genes and luteinization in vitro, GCs were treated with lysophosphatidic acid (LPA) (10 μM), testosterone (10 μM), estradiol (10 μM) or forskolin (10 μM) plus phorbol 12-myristate 13-acetate (PMA) (20 nM) for 2-24 h (Zhang et al., 2014) .
Immunofluorescence
Cultured GCs were fixed with 4% (v/v) paraformaldehyde for 20 min, permeabilized with 0.1% (v/v) Triton X-100 for 10 min, and blocked with 5% bovine serum albumin (w/v) for 30 min. The cells were then immunostained using primary antibodies against the indicated antibodies for 1 h, and followed by washing and fluorescent dye-conjugated secondary antibodies staining for 1 h. Then the cells were counterstained with propidium iodide (PI) (Molecular Probes ® , Life Technologies, Corp., Carlsbad, CA, USA) for 10 min, and were mounted on glass slides using SlowFade ® Gold
Antifade Reagent (Life Technologies) followed by microscopy. All mounted samples were examined and imaged on a confocal microscope LSM710 (Carl Zeiss) outfitted with a Plan-Apochromat ×40 or ×63 oil immersion objective lenses (Carl Zeiss).
Histology and immunohistochemistry
Ovaries were collected and fixed in 4% paraformaldehyde, embedded in paraffin and processed by routine procedures. Ovaries were sectioned at 5 μm and stained with hematoxylin and eosin (H&E). Immunohistochemistry was done using VectaStain Elite avidin-biotin complex method kits (Vector Labs, Burlingame, CA) as directed by the manufacturer. Sections were probed with primary antibodies against YAP1, MST1 or phospho-MST1/2 (all purchased from Cell Signaling, CA) and staining was done using the 3,3-diaminobenzidine peroxidase substrate kit (Vector Labs) as directed. Sections were counterstained with hematoxylin, dehydrated and mounted.
Western blot analyses
Cell extracts containing 30 μg proteins were resolved by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corp., Bedford, MA). After probing with primary antibodies the membranes were incubated with horseradish peroxidase-linked anti-rabbit antibodies (Cell Signaling Technologies, Danvers, MA), washed and the bound antibodies were visualized using the enhanced chemilumescent (ECL) substrate.
Luciferase assay and adenoviral infection
The plasmid for YAP1 luciferase assay was gifted by Dr KL Guan, and was described previously (Yu et al., 2012) . Cultured GCs in 24-well plates were transfected with this plasmids (500 ng/well) together with siRNAs (sh-control, and shYap1) using lipofectamine (Invitrogen, Carlsbad, CA) according to manufacturer's instructions. At 24 h after transfection, GCs were lysed in PBS containing 0.1% Triton X-100 and subjected to luciferase assay. Firefly luciferase activity was assessed with the Dual Luciferase Reporter Assay kit (E1910, Promega, Madison, WI), detected with the SpectraMaxL Luminometer (Molecular Devices, Sunnyvale, CA), and was normalized to Renilla luciferase activity (co-transfected as an internal control). For each experiment, luciferase reactions were done in triplicate. For adenoviral infection, GCs were washed and cultured in serum-free medium and infected with an adenoviral vector expressing YAP1 at a multiplicity of infection of 4:1. At 24 h post-infection, GCs were treated with forskolin (10 μM) and PMA (20 nM) for 4 h.
Cell growth assay
GCs were seeded in 96-well plates at 3 × 10 3 /well in DMEM containing 10% fetal bovine serum. After they adhered, cells were treated with siRNAs (sh-control, and shYap1) for 24 h and assessed for growth using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, 20 μl of MTT solution (5 mg/ml in PBS) was added into triplicate wells and cells were incubated for 4-6 h in an incubator. Absorbance at 490 nm was read with a microplate reader.
RNA isolation and real-time PCR
Total RNA was isolated from GCs of at least three mice. Reverse transcription was done using the SuperScript One-Step RT-PCR system with Platinum Taq kit (Invitrogen, Carlsbad, CA). The real-time PCR was performed using an Applied Biosystems (Foster City, CA) 7500 Real-Time PCR System. Relative mRNA levels were calculated by normalizing to the levels of endogenous β-actin mRNA (used as an internal control) using Microsoft EXCEL. For each indicated gene, the relative transcript level of the control sample (left-hand bar of each graph) was set as 1. The relative transcript levels of other samples were compared to the control, and the fold-changes shown in the graph. For each experiment, qPCR reactions were done in triplicate.
Ovulation and oocyte counting
To study ovarian responses to exogenous gonadotropins, postnatal day (PD) 21-23 female mice were injected intraperitoneally with five IU PMSG (Ningbo Sansheng Pharmaceutical Co., Ltd, China) to stimulate preovulatory follicle development followed 48 h later with five IU hCG (Ningbo Sansheng Pharmaceutical Co., Ltd, China) to stimulate ovulation. Ovulated oocytes were collected from oviducts and counted, at 16 h after hCG injection.
Statistical analyses
The data for real-time RT-PCR assays, luciferase assay and superovulation tests are represented as means ± SD. Data were analyzed by using GraphPad Prism Programs (ANOVA or t-test; GraphPad Prism, San Diego, CA) to determine significance. Values were considered significantly different if P ≤ 0.01.
Results
Acute hyperandrogenism blocks LH actions and causes oligo-ovulation in mouse
To study the effect of acute hyperandrogenism on ovulation, we injected PMSG-primed (44 h) pubertal mice with DHT, the major biologically active form of androgen, in a superovulation assay. The details of animal treatments were described in Materials and Methods. As shown in Fig. 1A , DHT injection decreased the numbers of oocytes being ovulated into the oviducts, as examined at 16 h after hCG injection. It has been reported that LH/hCG strongly induced the expression of ovulation-related genes in GCs of preovulatory follicles. Quantitative RT-PCR results showed that the mRNAs encoded for EGF-like factors (Amphiregulin (Areg), Epiregulin (Ereg) and β-cellulin (Btc)), which are intra-follicular mediators of LH actions, were significantly up-regulated in GCs isolated from mice treated with hCG for 4 h (Fig. 1B) . In addition, the LH-target genes essential for cumulus cell expansion (Ptgs2, Tnfaip6, Has2 and Ptx3) were also promptly induced to express in GCs after hCG treatment. However, the induction effect of hCG on these genes were remarkably compromised by DHT treatment in vivo (Fig. 1C) .
Results of ovarian histological analyses showed that DHT treatment inhibited the enlargement of follicle cavity and expansion of cumulus cells in preovulatory follicles, at 8 h after hCG treatment (Fig. 1D) . In those DHT-injected mice showing oligo-ovulation after superovulation treatments, oocytes were found trapped in large antral follicles that failed to rupture, at 16 h after hCG treatment (Fig. 1E) . However, detailed examination of these trapped oocytes indicated that meiotic maturation characterized by germinal vesicle breakdown (GVBD) was unaffected by DHT exposure. After ovulation, the remaining GCs of ovulated follicles formed corpus lutea (CLs) at 48 h post-hCG injection. However, DHT treatment blocked the CL formation (Fig. 1F) . Taken together, these results indicated that in our mouse model, acute hyperandrogenism blocks LH actions, including ovulation, luteinization and expression of ovulation-related LH-target genes.
We further studied whether after androgen withdrawal, these mice develop permanent PCOS like character. In this experiment, 21-day-old mice were given a single injection of DHT (100 μg). Control mice were injected with PBS. These mice were subjected to superovulation assay a week later. Mice were sacrificed at 16 h post-hCG (n = 6 for each group) and ovaries were isolated for histological analyses. Ovulated oocytes were collected from oviducts and counted. The DHT-treated mice ovulated similar numbers of oocytes as the control after DHT withdrawal, and they have normal ovarian histology after the superovulation treatment (Fig. 1G ).
Testosterone and estrodial activate YAP1 in GCs
The underlying mechanism by which hyperandrogenism blocks LH actions is unclear before. We investigated if the PCOS-associated factor YAP1 is regulated by testosterone and is potentially involved in follicle development and ovulation. In cultured primary GCs, YAP1 protein is distributed in both cytoplasm and nuclei. As a positive control, the known YAP1 activator LPA induced significant translocation of YAP1 from cytoplasm to nuclei ( Fig. 2A) , indicating that YAP1 activity is regulated by cytoplasm-nuclear transport, as being reported in other cell types (Yu et al., 2016) . However, testosterone induced a prompt translocation of YAP1 from cytoplasm to nuclei within 0.5 h. The nuclear localization of YAP1 remained at 2 h after testosterone treatment. YAP1 re-distributed to cytoplasm at 24 h after testosterone treatment (Fig. 2B) . Because testosterone is actively transformed in to estrogen by aromatase in vivo, and most patients of hyperandrogenism also suffer from estrogen excess, we investigated the effect of estrodial on YAP1 localization in GCs. Similar to testosterone, estrodial also induced nuclear enrichment of YAP1 protein (Fig. 2C) .
Nuclear translocation of YAP1 indicates its activation. Therefore, we directly assessed the effect of testosterone (T) and estradiol (E2) on YAP1 activity by luciferase assay. As shown in Fig. 2D , testosterone and estradiol dramatically increased the transcriptional activity of a YAP1 luciferase reporter in GCs. However, this effect was compromised in GCs pre-treated with Yap1 siRNAs (siYap1). In addition, RNAi depletion of YAP1 also caused a delay of GC proliferation rate (Fig. 2E) . These results suggest that testosterone (T) and estradiol (E2) may stimulate GC proliferation by activating YAP1. Although testosterone and extradiol increased YAP1 activity, they do not seem to regulate YAP1 protein levels, as shown by Western blotting using isolated GCs (Fig. 2F) and immunohistochemistry on ovarian sections (Fig. 2G) .
Surprisingly, however, when GCs were treated with forskolin plus (PMA), which is a well-established stimulus mimicking LH actions in vitro, YAP1 protein was promptly exported from nuclei within 0,5 h, and maintained a pattern of cytoplasmic localization as long as 24 h (Fig. 2H) . These results indicate that steroid sex hormones (testosterone and estrodial) and LH signaling play opposite roles in regulating YAP1 activity, and suggest that hyperactivation of YAP1 may involved in hyperandrogenism-induced oligo-ovulation.
LH/hCG inactivates YAP1 through ERK1/2 signaling cascade
Because the results so far suggest that YAP1 in GCs may involve in follicle growth and ovulation, we investigated the expression pattern of YAP1 in developing ovaries. The immunohistochemistry results showed that YAP1 protein was highly expressed in GCs of growing secondary follicles as early as postnatal day (PD)-14 (Fig. 3A) . At PD21, YAP1 levels were high in all preantral follicles. After PMSG-treatment, YAP1 was continually expressed in GCs of large antral follicles. However, hCG injection caused a significant decrease of YAP1 protein levels in GCs of preovulatory follicles and in luteal cells after ovulation. As an internal control, the YAP1 levels in oocytes were not affected by hCG treatment (Fig. 3A) . The localization of YAP1 is known to be associated with phosphorylation. Therefore, we also detected the levels of phosphorylated YAP1. Western blotting showed a decrease of total and phospho-YAP1 levels in GCs after hCG treatment (Fig. 3B) . Interestingly, the hCGinduced reduction of YAP1 expression was blocked by Erk1/2 knockout in GCs driven by Cyp19-Cre (Fig. 3A and B) .
In another experiment, forskolin/PMA treatment also induced a decrease of YAP1 levels in cultured GCs. However, this effect was blocked by U0126, a specific inhibitor of ERK1/2 activation (Fig. 3C) . In addition to decrease YAP1 levels, forskolin/PMA treatment also downregulated the YAP1 activity, as shown by luciferase assay (Fig. 3D) .
In addition to YAP1 protein levels, we also examined the mRNA expression changes of Yap1 and its target genes. Tead1 and Ctgf are established YAP-target genes. TEAD1 is a cofactor of YAP1 in stimulating transcription, and CTCF has been shown to be required for follicle development and ovulation (Nagashima et al., 2011; Yu et al., 2016) . In GCs isolated from in vivo, hCG treatment decreased the levels of transcripts encoded for Yap1 as well as its target Tead1 and Ctgf (Fig. 3E) .
The YAP1 negative regulator Mammalian sterile-20-like-1/2 (MST1/2) are activated in preovulatory follicles It has been reported that YAP1 is negatively regulated by protein kinases MST1 and MST2, the upstream components in Hippo signaling pathway (Dai et al., 2015) . Our immunohistochemistry results showed that MST1 is highly expressed in GCs at all developmental stages (Fig. 4A) . Specifically, however, levels of phospho-MST1/2 were upregulated in mural GCs of preovulatory follicles after hCG injection (Fig. 4B) . Western blotting results in GCs isolated from in vivo further confirmed that the levels of phospho-MST1/2, instead of total MST1 levels, were up-regulated by hCG (Fig. 4C ).
YAP1 inactivation facilitates LH actions in vitro
To directly assess the impact of YAP1 activity on LH actions, we overexpressed YAP1 protein in cultured GCs by infecting the cells with adenovirus encoding Yap1 (Ad-Yap1) (Fig. 5A) . Quantitative RT-PCR results showed that the indicated LH target genes involved in ovulation were up-regulated by forskolin/PMA treatment within 4 h. However, the induction of these genes was blocked in GCs over-expressing YAP1 (Fig. 5B) .
We also depleted Yap1 expression in cultured primary GCs by RNA interference (Fig. 5C) , and evaluated its effect on the expression of LH target genes. Quantitative RT-PCR results showed that the LH target genes involved in luteinization, including Cyp11a1, Star, Lhcgr and Pgr, were up-regulated between 24 and 52 h after Yap1 RNA interference, even without LH stimulation (Fig. 5D ). More significantly, the Yap1-depleted GCs showed increased responsiveness to forskolin/PMA treatments: the induction levels of indicated LH-target genes were higher in Yap1-depleted GCs than in control GCs (Fig. 5E ). In consistent with the anti-ovulation effect of DHT, testosterone inhibited forskolin/PMA-induced expression of LH-target genes. However, the inhibitory effect of testosterone is partially relived in Yap1-depleted GCs (Fig. 5E ). Taken together, these results suggest that YAP1 inactivation is a prerequisite for LH actions, and high levels of steroid sex hormones inhibit ovulation by hyper-activating YAP1.
Discussion
Key features of PCOS include hyperandrogenism, oligo-ovulation and the development arrest of multiple preantral/early antral follicles in the ovary. Although the etiology of PCOS remains unclear, a plausible explanation is that signals that control follicle development are deregulated and therefore lost proper responsiveness to endogenous gonadotropins. Our results suggest that YAP1 is a previously unrecognized regulator of ovarian follicle development, and is involved in the pathogenesis of PCOS. Physiologically, YAP1 in GCs of secondary/preantral follicles is activated by steroid sex hormones and may promotes follicle growth, and probably also prevents their atresia. During ovulation, however, LH takes control of the follicle development program. LH inactivates YAP1, terminates GC proliferation and triggers the terminal differentiation of GCs into luteal cells. In contrast, androgen or estrogen excess induces a hyperactivation of YAP1, which antagonizes the LH actions.
Although we showed that YAP1 nuclear translocation and activation was promptly triggered by testosterone and estrodiol, the detailed signal transduction process is unclear so far. Both steroid hormones and Hippo-YAP1 pathways are involved in a wide range of biological processes. Our study shed the first light that they cooperate in regulating development or homeostasis in the ovary. We suggest that the interplay of steroid hormones and YAP1 also exists in organs other than the ovary. The biochemical mechanisms by which steroid hormones activate YAP1 will be an interesting topic to address in further investigations.
The risk for certain carcinomas such as endometrial and ovarian cancers is increased in PCOS patients (Li et al., 2006) . Our recent findings indicate that YAP1 is a key ovarian cancer oncogene and that YAP1/ TEAD4 co-expression may be a predictor of a poor prognosis for human ovarian cancer (Xia et al., 2014) . Continuous YAP1 activation induces increased ovarian cancer cell proliferation, resistance to cisplatin-induced cellular apoptosis and anchorage-independent growth. YAP1/TEAD coactivator also regulates ovarian cancer initiated cell pluripotency and chemo-resistance. In the current study, we showed that androgen or estrogen excess strongly activates YAP. Taken together, these results suggest that YAP1 may be the link between the endocrine disorder of PCOS and ovarian cancers.
The pituitary LH surge triggers a series of related biological events that eventually lead to ovulation, including oocyte meiotic resumption, cumulus cell expansion, follicle rupture and luteinization Zhang et al., 2015) . Our previous studies indicated that these LH actions are mediated mainly by RAS-ERK1/2 signaling cascade (Fan et al., 2008 (Fan et al., , 2009 ) and its downstream effectors, such as the transcriptional factors C/EBPα/β and CITED4 (Fan et al., 2011; Zhang et al., 2014) . In this study we elucidate a novel LH action in preovulatory follicles, in which LH induces the YAP1 inactivation through ERK1/2 cascade. LH appears to achieve this action by activating MST1/2, the negative regulator of YAP1 in Hippo signaling pathway, in mural GCs. This mechanism is supported by previous discoveries that ERK1/2 cascade has crosstalk with MST1/2 in multiple cell types .
Furthermore, our results strongly suggest that LH-triggered YAP1 inactivation is essential for GC luteinization and ovulation. A physiological function of YAP1 is to maintain the GCs at a non-luteinized and highly proliferative state. Therefore, YAP1 has to be inactivated by the preovulatory LH surge to allow the initiation of ovulation program in fully grown follicles. In this scenario, the function and regulation of YAP1 is similar to that of CTNNB1 (β-catanin) in several aspect. As a key component of Wnt signaling pathway, CTNNB1 is activated by FSH in GCs and facilitates follicle growth and estrogen biosynthesis, but is inactivated before ovulation. Induced hyperactivation of CTNNB1 causes anovulation in mouse . It is noteworthy that CTNNB1 and YAP1 activity are usually co-regulated, and they also activate each other . Taken these findings together, we proposed that the follicle development program is delicately regulated by a signal network involves Wnt, Hippo and ERK1/2 pathways, which are regulated by steroid hormones (testosterone and estradiol) and gonadotropins (FSH and LH). Any endocrine disorders will cause the deregulation of this network and lead to the sterilityprone pathogenesis such as PCOS.
